Phaseline

Companies › Spectrum Pharmaceuticals

Spectrum Pharmaceuticals: clinical trials, targets and expected readouts

1 active drug program in 1 registered trial: 1 Phase 2; Oncology; next expected readout Oct 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
Eflapegrastim
Granulocyte colony stimulating factor receptor agonist
CSF3RPhase 2Solid TumorsOct 2027

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT04570423EflapegrastimPhase 2Solid TumorsOncologyOct 2027

From the company's SEC filings

Complete response letters from FDA

Private offerings reported to the SEC (Form D)

Targets

CSF3R (1)

Companies with the same targets

Nanjing King-Friend Biochemical Pharmaceutical CSL Behring Savara Qilu Pharmaceutical Kexing Biopharm Yaqrit

Companies built like this

Buzzard Pharmaceuticals Cellvax Therapeutics Newish Technology (Beijing) BrainChild Bio TVAX Biomedical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.